Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies
Department of Neurology
Acute Disease; Alopecia; Animals; Clinical Trials as Topic; Cyclophosphamide; Cystitis; Disease Models, Animal; Drug Evaluation; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Lymphocyte Activation; Male; Multiple Sclerosis; Nausea; Pilot Projects; Rats
Neurology | Neuroscience and Neurobiology
Cyclophosphamide (CY) has been shown to reverse the signs of experimental allergic encephalomyelitis (EAE) even after the onset of neurological deficits. Because of the analogy of EAE to exacerbations of multiple sclerosis (MS) a clinical trial of CY in acute MS exacerbations was undertaken. A 'sequential criterion' method was used to minimize the size of sample needed for this pilot study. CY failed to alter significantly the course of acute exacerbations of MS. Possible reasons for this failure, and the value of the sequential criterion method in pilot studies, are discussed.
J Neurol Neurosurg Psychiatry. 1975 Jun;38(6):592-7.
Journal of neurology, neurosurgery, and psychiatry
Drachman DA, Paterson PY, Schmidt RT, Spehlmann RF. (1975). Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. Neurology Publications. Retrieved from https://escholarship.umassmed.edu/neuro_pp/200